Glycemic load impacts the response of acquired resistance in breast cancer cells to chemotherapeutic drugs in vitro.

Resisting chemotherapy is a significant hurdle in treating breast cancer. Locally advanced breast cancer patients undergo four cycles of Adriamycin and Cyclophosphamide, followed by four cycles of Paclitaxel before surgery. Some patients resist this regimen, and their cancer recurred.